Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Riovant Sciences

Hear from her: Changing what’s possible for Women in Healthcare

Medscape Education Global

Hear from her: Meet your hosts

Every day, women leaders are changing the healthcare landscape for the better. Our Women in Healthcare Leadership Podcast Series features some of the women working to elevate equity, achieve gender...

Medscape Education Global

- PMLiVE

New genetic variants linked to prostate cancer in men with African ancestry

A dataset was compiled for the research containing DNA from over 944,000 men

- PMLiVE

Takeda’s enzyme replacement therapy approved by FDA for rare blood clotting disorder

The ultra-rare inherited disease is estimated to affect fewer than 1,000 people in the US

- PMLiVE

Takeda’s Fruzaqla receives FDA approval for metastatic colorectal cancer

More than 150,000 new cases of colorectal cancer will be diagnosed in the US in 2023

- PMLiVE

Takeda announces EC approval for Adcetris combination in Hodgkin lymphoma

The ADC has been approved alongside doxorubicin, vinblastine and dacarbazine

- PMLiVE

Scientists discover way to reverse drug resistance in prostate cancer

Targeting ‘hijacked’ white blood cells could reverse drug resistance and slow tumour progression

- PMLiVE

International study reveals 11 new genes linked to aggressive prostate cancer

Findings from the study could improve treatment options for patients with prostate cancer

- PMLiVE

Takeda announces CHMP recommendation for Adcetris in Hodgkin lymphoma

The ADC has been recommended with doxorubicin, vinblastine and dacarbazine

- PMLiVE

Bristol Myers Squibb reveals plans to double number of drugs in registrational trials

The drugmaker expects to expand its research pipeline from six to 12 over next 18 months

- PMLiVE

Takeda announces positive phase 2b results for TAK-279 in psoriatic arthritis

Approximately 10 million people worldwide are affected by the inflammatory disease

- PMLiVE

ICR study supports use of new radioactive treatment for advanced prostate cancer

Experts are calling for NICE to assess if the treatment should be made available on the NHS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links